Lilly Announces Webcast to Provide Alzheimer's Disease Update at AD/PD Conference
Eli Lilly and Company (NYSE: LLY) will hold a webcast on March 15, 2021 at 10:30 a.m. Eastern Time to discuss its Alzheimer's disease program, including results from the Phase 2 TRAILBLAZER-ALZ study for donanemab. This information will be shared at the 15th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD). Both investors and the public can access the live webcast via the company's website, with a replay available afterward.
- Webcast scheduled for March 15, 2021, may enhance investor relations.
- Discussion on Alzheimer's program may indicate ongoing commitment to research.
- None.
INDIANAPOLIS, Feb. 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, March 15, 2021 to provide an update on its Alzheimer's disease program and discuss results from the Phase 2 TRAILBLAZER-ALZ study for donanemab being presented at the 15th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD). The webcast will begin at 10:30 a.m. Eastern Time.
Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com. F-LLY
Refer to: | Mark Taylor; mark.taylor@lilly.com; (317) 276-5795 (Media) |
Kevin Hern; hern_kevin_r@lilly.com; (317) 277-1838 (Investors) |
View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-announces-webcast-to-provide-alzheimers-disease-update-at-adpd-conference-301222615.html
SOURCE Eli Lilly and Company
FAQ
What is the date and time of the Eli Lilly Alzheimer's disease program webcast?
Where can I access the Eli Lilly Alzheimer's disease webcast?
What will be discussed during the Eli Lilly webcast on March 15, 2021?
What is the significance of the TRAILBLAZER-ALZ study for Eli Lilly?
